A novel,integrated PET-guided MRS technique resulting in more accurate initial diagnosis of high-grade glioma

Abstract

Glioblastoma multiforme (GBM) is the most common and lethal malignant glioma in adults. Currently, the modality of choice for diagnosing brain tumor is high-resolution magnetic resonance imaging (MRI) with contrast, which provides anatomic detail and localization. Studies have demonstrated, however, that MRI may have limited utility in delineating the full tumor extent precisely. Studies suggest that MR spectroscopy (MRS) can also be used to distinguish high-grade from low-grade gliomas. However, due to operator dependent variables and the heterogeneous nature of gliomas, the potential for error in diagnostic accuracy with MRS is a concern. Positron emission tomography (PET) imaging with ¹¹C-methionine (MET) and ¹⁸F-fluorodeoxyglucose (FDG) has been shown to add additional information with respect to tumor grade, extent, and prognosis based on the premise of biochemical changes preceding anatomic changes. Combined PET/MRS is a technique that integrates information from PET in guiding the location for the most accurate metabolic characterization of a lesion via MRS. We describe a case of glioblastoma multiforme in which MRS was initially non-diagnostic for malignancy, but when MRS was repeated with PET guidance, demonstrated elevated choline/N-acetylaspartate (Cho/NAA) ratio in the right parietal mass consistent with a high-grade malignancy. Stereotactic biopsy, followed by PET image-guided resection, confirmed the diagnosis of grade IV GBM. To our knowledge, this is the first reported case of an integrated PET/MRS technique for the voxel placement of MRS. Our findings suggest that integrated PET/MRS may potentially improve diagnostic accuracy in high-grade gliomas.

Keywords

Glioblastoma multiforme MR spectroscopy imaging PET imaging

Get full access to this article

View all access options for this article.

References

National Comprehensive Cancer Network. NCCN Guidelines Central Nervous System Cancers. The NCCN Guidelines, http://www.nccn.com (2014, accessed 21 April 2015).

Waters

Gonda

Reddy

. Diagnostic yield of stereotactic needle-biopsies of sub-cubic centimeter intracranial lesions. Surg Neurol Int 2015; 4: 176–181.

McKnight

Von Dem Bussche

Vigneron

. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002; 97: 794–802.

Chen

White

Farid

. Pre-operative cellularity mapping and intra-MRI surgery: Potential for improving neurosurgical biopsies. Expert Rev Med Devices 2015; 12: 1–5.

Singhal

Narayanan

Jacobs

. 11C-Methionine PET for grading and prognostication in gliomas: A comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 2012; 53: 1709–1715.

Dowling

Bollen

Noworolski

. Preoperative proton MR spectroscopic imaging of brain tumors: Correlation with histopathologic analysis of resection specimens. Am J Neuroradiol 2001; 22: 604–612.

Huang

Neagu

Reardon

. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immune/targeted therapy—detecting illusive disease, defining response. Front Neurol 2015; 6: 1–16.

Scott

Brasher

Sevick

. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002; 59: 947–949.

Alger

Barker

. Clinical proton MR spectroscopy in central nervous system disorders. Radiology 2014; 270: 658–679.

10.

Loda

Pession

. Membranous expression of glucose transporter-1 protein (GLUT-1) in embryonal neoplasms of the central nervous system. Neuropathol Appl Neurobiol 2000; 26: 91–97.

11.

Pardo

Aronen

Fitzek

. Correlation of FDG-PET interpretation with survival in a cohort of glioma patients. Anticancer Res 2004; 24: 2359–2366.

12.

Kobayashi

Hirata

Yamaguchi

. Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients. Eur J Nucl Med Mol Imaging 2015; 42: 1071–1080.

13.

Hou

Masuda

. Kinetic analysis of tRNA methyltransferases. Methods Enzymol 2015; 560: 91–116.

14.

De Witte

Goldberg

Wikler

. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001; 95: 746–750.

15.

Pirotte

Levivier

Goldman

. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: A survival analysis in 66 consecutive patients. Neurosurgery 2009; 64: 471–481.

16.

Pirotte

Goldman

Massager

. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 2004; 45: 1293–1298.

17.

Sood

Gupta

Tsiouris

. Advanced magnetic resonance techniques in neuroimaging: Diffusion, spectroscopy, and perfusion. Semin Roentgenol 2010; 45: 137–146.

18.

Hourani

Brant

Rizk

. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults? Am J Neuroradiol 2008; 29: 366–372.

19.

Law

Yang

Wang

. Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 2003; 24: 1989–1998.

20.

Chawla

Wang

Wolf

. Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. Am J Neuroradiol 2007; 28: 1683–1689.

21.

Roessler

Gatterbauer

Becherer

. Surgical target selection in cerebral glioma surgery: Linking methionine (MET) PET image fusion and neuronavigation. Minim Invas Neurosurg 2007; 50: 273–280.